INTRODUCTION
The corpus callosum is the main myelinated fiber tract in the human brain commissures between homotopic and heterotopic regions of the cerebral hemispheres. Its development begins early during brain ontogenesis, from the 13 th to 20 th weeks after conception (Edwards et al., 2014) . Corpus callosum agenesis (CCA) is among the most common brain morphological anomalies affecting about one out of 4000 newborns and its prevalence reaches 2% to 3% of individuals with intellectual disability (ID) (Grogono, 1968; Schaefer and Bodensteiner, 1992; Wang et al., 2004) . CCA is extremely heterogeneous both clinically and etiologically. Genetic causes are usually identified in 30-45% of CCA, including chromosomal rearrangements (10-20%) and Mendelian conditions (30%) (Edwards et al., 2014; Palmer and Mowat, 2014) . Several chromosomal alterations and more than 300 different causative genes have been reported to date (Edwards et al., 2014; Heide et al., 2017) .
However, in a relatively large proportion of cases, the genetic defect remains unidentified. We report here a new likely causative mutation p.Gly424Arg (G424R) in the X-linked p21activated kinase PAK3 gene in a patient with CCA and severe ID, and in his sibling fetus with hydrocephaly and CCA.
More than ten PAK3 mutations have been reported to date in mild to severe ID with or without brain anomalies such as microcephaly, macrocephaly, and callosal agenesis (Allen et al., 1998; Bienvenu et al., 2000; Cartwright et al., 2017; Gedeon et al., 2003; Hertecant et al., 2003) . Even if PAK3 is already known as a key regulator of synaptic plasticity and dendritic spine dynamics, its precise role in neurodevelopmental processes remains elusive (Kreis and Barnier, 2009 ).
PAK3 is a multi-functional protein whose functions depend on its kinase activity and on its different substrates. It also possesses scaffolding functions with partners involved in signalling pathways (Kreis and Barnier, 2009) . Several biochemical defects related to pathogenic variants have been characterized including alteration of its kinase activity, protein stability, GTPase binding, dimer formation, and MAPK activation Kreis et al., 2007; Magini et al., 2014; Thévenot et al., 2011) . In order to elucidate the genotype-phenotype relationship of affected patients, and more precisely to decipher the molecular bases of PAK3-mediated CCA, we performed a comparative analysis at the structural, biochemical and cellular levels between two mutation types: i) two missense mutations, K389N and the new G424R mutation, both responsible for severe ID and brain anomalies including microcephaly and CCA and ii) another missense mutation, A365E, responsible for nonsyndromic mild ID (Gedeon et al., 2003; Magini et al., 2014) . These three mutations are located in the C-terminal lobe of the kinase domain but outside the catalytic site. We analysed their phylogenic conservation, impact on protein structure and their consequences on catalytic functions. In this study, we also demonstrate that although these three mutations totally suppress PAK3 catalytic activity, only the two mutations causing severe ID and CCA maintain a wild-type (WT)-like protein stability, increase αPIX/ARHGEF6 binding, impair adhesion point dynamics, and inhibit cell migration.
The following plasmids were previously described: pcDNA3-HA-PAK3-WT encodes the HA-tagged wild type PAK3 protein, the pcDNA3-HA-PAK3-K297L encodes K297L kinase dead mutant and pcDNA3-HA-PAK3-A365E encodes a ID-mutated PAK3 variant (Kreis et al., 2007; Rousseau et al., 2003) . The two mutants PAK3-K389N and PAK3-G424R were generated from pcDNA3-HA-PAK3-WT plasmid with Q5 high-fidelity DNA polymerase (NEB, #M0491S) by PCR and the primers set (5'-CCAAGTGATCCACAGAGACATAAATAGCGACAACATTCTCCTCG-3' and 5'-CGAGGAGAATGTTGTCGCTATTTATGTCTCTGTGGATCACTTGG-3') and the primer set (5'-GTAAACGAAGCACTATGGTGAGAACTCCCTATTGGATGGCAC-3' and 5'-GTGCCATCCAATAGGGAGTTCTCACCATAGTGCTTCGTTTAC-3'), respectively using Quick change mutagenesis protocols. Mutated PAK3 gene sequences were verified by sequencing (Eurofins-GATC Company). The PIX interaction mutant (PIM) pcDNA3-HA-PAK3-P194G-R195A was generated from pcDNA3-HA-PAK3-WT using a Phusion sitedirected mutagenesis kit (Thermofischer #F541) with the oligonucleotide set (5'-GGAGCTCCAGAGCATACAAAATCAATCTATACTCGC-3' and 5'-TGCAATGACAGGCGGGGGTTC-3'). Lentiviral vectors (pHAGE-HA-PAK3) used for COS7 cells infection were derived from pHAGE backbone using a "Gateway"® cloning protocol (Invitrogen) by introducing specific AttB sequences using the pcDNA3-HA-PAK3 plasmids as templates (WT, K297L, A365E, K389N and G424R) and the oligonucleotide set (5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGCTAGCTATCC-3' and and phosphatase inhibitors mixture. PAK3 proteins were HA-affinity purified, washed as previously described and washed one more time with kinase buffer (25 mM HEPES pH7.4, 25 mM MgCl 2 and 25 mM β-glycerophosphate). Immunoprecipitates were incubated in kinase buffer containing 40 μM ATP and 5 μCi of [γ-32 P] ATP for 20 minutes at 30 °C in presence of 3 μg of myelin basic protein (MBP) as a substrate. Samples were then boiled in SDS-Laemmli buffer to stop the reaction and the products were resolved by 12 % SDS-PAGE. Gels were dried and exposed to autoradiography. Immunoblot analysis were performed using anti-GFP (Millipore, #MAB3580), anti-βPAK (N-19, Santa Cruz, #SC-1871), anti-HA (Cell Signaling Technology, #2367). Membranes were then incubated using anti-mouse (Biorad, #172-1011), anti-goat (Pierce, PA1-86326) and/or anti-rabbit (Biorad, #75011) peroxidase-linked secondary antibodies. Membranes were then revealed with Luminata Crescendo (Millipore).
To assess the protein stability, PAK3 expression was induced by doxycycline in COS7-Lv-PAK3 cells during 48 h. PAK3 protein synthesis was stopped by doxycycline withdrawal, cells were lysed at the indicated time and decrease of PAK3 protein level was monitored by western blot on 10 µg of Total cell lysates (TCL) proteins as described above, using anti-HA antibodies and with anti-α-tubulin (Sigma, T6199) western blot as loading control. For MAP Kinase activation, PAK3 expression in Lv-transduced COS7 cells was induced by doxycycline for 2 days, or not; cells were cultured overnight in low serum conditions, and then treated, or not, with serum (10% final foetal bovine serum) for ten minutes before to be washed (ice-cold PBS with 0.1 mM orthovanadate) and lysed with the same lysis buffer than for kinase assays and proteins samples were processed by the same method (see above). ERK activation was analysed by western blot with anti phospho-ERK antibodies (T202/Y204, Cell Signaling, #4370), and then sample loading assessed by anti-α tubulin revelation.
To test αPIX and βPIX binding, HEK cells were cotransfected with the plasmids of interest with Lipofectamine as described above and controls were done with a PAK3 variant bearing J o u r n a l P r e -p r o o f Journal Pre-proof the double point mutation (P194G-R195A) in the proline-rich segment known to totally suppress PAK/PIX interaction and with a βPIX construct with a deletion of the SH3 domain (ΔSH3). Transfected cells were lysed 36 h later with a modified Robert's lysis buffer containing 0.1% Triton X-100, 10% glycerol, 20 mM Tris-HCl pH8.0, 137 mM NaCl, 50 mM NaF supplemented with protease and phosphatase inhibitors mixture. After 15 min on ice, lysates were cleared by centrifugation at 10000 g for 15 min. A Bradford protein assay (Biorad) was then performed to measure the protein concentration. TCL were immunoprecipitated overnight at 4 °C using monoclonal anti-HA agarose antibody (Sigma-Aldrich, #A2095). Anti-HA immunocomplexes were then washed four times with lysis buffer (previously described). Protein samples were separated by 10% SDS-PAGE. Immunoblot analysis were performed using anti-β-actin (Santa Cruz, #SC-69879), anti-HA (Cell Signaling Technology, #2367), anti-FLAG (Sigma, #F7425) primary antibodies. Membranes were then incubated using anti-mouse (Biorad, #172-1011) peroxidase-linked secondary antibodies.
Membranes were then revealed with Luminata Crescendo (Millipore). Quantification was assessed using a CCD camera (Fusion FX imaging system, Vilber Lourmat) and analysis was performed with ImageJ software. Amounts of co-immunoprecipitated FLAG-PIX proteins, detected and quantified by western blot were expressed relatively to HA-immunoprecipitated PAK3 proteins.
Cell imaging
COS7-Lv-PAK3 cells were plated at low density on glass coverslips and protein expression was induced with doxycycline during 24 h in half conditions. Cells were fixed with 4% pformaldehyde for 15 min, washed with PBS and permeabilised with 0.1% Triton X-100 and 0.1% Tween 20 for 15 min at room temperature, then blocked with 0.3% bovine serum albumin (BSA) for 2h at room temperature before an incubation in 0.1% Tween 20, 0.1%
BSA with anti-paxillin (Millipore/Upstate, #05-417) and anti-HA (Roche, #1867423) antibodies overnight at 4 °C. Cells were then washed and incubated for 2h at room Wound healing assay COS7-Lv-PAK3 cells were plated at 7.10 5 cells/mL as recommended by Ibidi using a culture insert with two wells separated by a 500 μm gap (Ibidi GmbH, #81176). One day after, 50 μM of Cytosine Arabinoside (AraC) was added to each well and 2 µg/mL of doxycycline to half conditions. 24 h later, insert was removed, and wells were washed twice with PBS and a fresh complete growth medium (described before) with AraC and doxycycline (in induced wells) was added. Pictures were then taken using a Leica DMI6000B microscope at 0, 3 and 5 h after insert withdrawal. Migration analysis was performed with ImageJ software: each induced cell line migration was normalized and compared to its non-induced control.
To quantify cell apoptosis in these conditions, we performed anti-cleaved caspase 3 labelling using the following protocol: cells were fixed with 4% p-formaldehyde for 15 min, washed with PBS and permeabilised/blocked with 5% goat normal serum and 0.3% Triton for 2h at room temperature before an overnight incubation at 4°C in PBS with 1% BSA and 0.3%
Triton containing rabbit anti-cleaved caspase 3 antibody (Cell Signaling #9664). Cells were then washed and incubated for 2h30 in PBS with 1% BSA and 0.3% Triton containing goat anti-rabbit A568 antibody (Mol Probes #A11036). Slips were mounted on slides with Fluoromount + Dapi (eBioscience, #00-4959-52), and cells were imaged using a Leica DMI6000B microscope and pictures were analysed with ImageJ software.
Statistical analysis
Biochemical experiments (protein stability and protein interaction assay) and wound healing assay were conducted at least three times and data are presented as mean ± SEM. Normal The patient is the second son of healthy and unrelated parents from Maghreb ( Figure   1A ). From a first consanguineous union, the mother had a healthy daughter. The mother had one healthy sister and two healthy brothers. The maternal grandmother had two brothers including one with ID who died at 11 years old and one who died at birth. The first pregnancy of the couple was terminated at 34 weeks of gestation after prenatal ultrasound diagnosis of CCA associated with severe hydrocephaly in a male fetus. Neuropathological examination showed that the brain weight was over the 95 th centile and confirmed a subtotal CCA with presence of Probst bundles, a septal dysgenesis associated with triventricular dilatation, a massive gliosis of white matter and subependymal cystic lesions. The second pregnancy gave birth to a premature boy who died at birth. During the third pregnancy, CCA was diagnosed by ultrasound. The parents decided to continue the pregnancy and the patient was born eutrophic at 39 weeks of gestation (weight 3,595 g, length 47 cm, head circumference 33 cm).
The first years of life were characterized by global development delay (the patient walked at 3 years, said his first words at 5 years) and behavior disturbances (including frequent hand stereotypies). At age of 7 years, the patient's weight was 19 kg (-1 SD), height at 108 cm (-2 SD) and head circumference at 47 cm (-3 SD). He had ID and spoke only a few words. At neurological examination, he had contractures of knees and hips with normal tendon reflexes.
Brain MRI at the age of 6 years showed a short corpus callosum with global hypoplasia predominating in its posterior part ( Figure 1B) . He had no other brain or extra-cerebral malformations. Clinical examinations of the patient over a long period did not reveal any ichthyosis or other cutaneous abnormalities. Karyotyping and microarray of the patient were normal. In search for the etiology, we performed trio-based whole exome sequencing and identified a single nucleotide variation in the PAK3 gene (ChrX(GRCh37):g.110439731G>A, c.1270G>A in the NM_001128166 transcript, p.Gly424Arg) inherited from his mother.
J o u r n a l P r e -p r o o f
Journal Pre-proof Familial segregation showed that the sibling aborted fetus with hydrocephaly and CCA also carried the mutation at hemizygous state whereas the healthy maternal uncle did not. This mutation is absent from the control subject databases GnomAD, dbSNP, and 1000 Genome and was not found in the clinical database ClinVar (1000 Genomes Project Consortium et al., 2012 Landrum et al., 2018; Sherry et al., 2001) . Identified variant was deposited in the ClinVar Database where it is publicly available and can be found with accession number SCV000897773 for c.1270G>A at the following link:
https://www.ncbi.nlm.nih.gov/clinvar/variation/626256/.
The conserved G424 residue forms the hinge of the activation loop of the catalytic domain
The c.1270G>A mutation leads to a non-synonymous change (p.Gly424Arg). This G424 residue is totally conserved among the human PAK paralogous (PAK1/2/4/5/6) and
among the other PAK orthologous proteins in vertebrate and invertebrate organisms (Figures 2A and S1A). This residue is conserved in around half of the human kinome (57%), especially in the AGC and STE kinase families ( Figure S1B ). In silico prediction analyses indicated that the variant should be disease-causing since Polyphen-2 and SIFT/Provean predicts a damaging effect with any substitution of this residue (Polyphen-2: 1.0; SIFT:0.00 scores) (Adzhubei et al., 2013; Kumar et al., 2009) . The G424 residue is located in the kinase domain, like most of the previously described PAK3 mutations. It is located at the C-terminal hinge ter Gly424 (Φ = 132, ψ = -160) is in a "Glycine favoured" region signifying that at the position 424 it can only be a glycine residue ( Figure S2 ) (Lovell et al., 2003) . Thus, mutation to Arg424, a residue that cannot function as a hinge is predicted to impair the conversion of PAK3 to its active conformation without affecting its stability and likely affects the dependent processes from this segment, particularly the kinase activity. The two other mutations included in this study are also located in the kinase domain. Ala365 is buried inside the lobe, where its mutation into a bulkier Glu residue may result into structural misfolding. K389N is located at the tip of the loop that carries Arg386, a residue that is critical for the stabilization of the activation loop by binding to phosphorylated Thr421 in the activation loop. Its mutation to Asn, a residue known to support a wide range of main chain conformations, is likely to alter the stability of PAK3 and /or the conformation of the phosphorylated, active form of the kinase.
The K389N and G424R mutations abrogate kinase activity without affecting protein stability
Since mutations in the activation segment may have opposite effects, we analysed the effect of the G424R mutation on kinase activity (Dixit and Verkhivker, 2014) . We compared the new G424R variant to the two previously described A365E and K389N mutations, which are both located in the kinase domain but lead to differential phenotypes, i.e. nonsyndromic mild ID and severe ID associated with CCA, respectively. From this point on, the G424R and K389N variants will be coined as "severe PAK3" mutations (for "associated with severe phenotypes") and the A365E as "mild PAK3" mutation (for "associated with a mild phenotype"). These PAK3 mutants were transiently co-expressed in HEK cells with constitutively active or dominant negative forms of the CDC42 GTPase. Controls included the WT PAK3 protein and the K297L kinase-dead mutant, generated by disruption of the ATPbinding site of the catalytic domain and recurrently used as control for kinase activity. Upon co-expression with the constitutively active CDC42-V12 mutant, all three J o u r n a l P r e -p r o o f Journal Pre-proof immunoprecipitated PAK3 mutant proteins displayed no kinase activity (like the negative control K297L mutant), whereas the WT protein displayed high activity ( Figure 3 ). The loss of kinase activity may contribute to the pathogenicity of the three mutants but would not explain the different clinical phenotypes associated with them.
As previously suggested by Magini and colleagues, the stability of mutated PAK3 proteins may in part explain the severity of the disease (Magini et al., 2014) . To explore this hypothesis, we tested the degradation time course of these proteins without affecting the biosynthesis of other cellular proteins using a new approach based on the withdrawal of the antibiotic that positively controls the transcription of the gene of interest. We established COS7-Lv-PAK3 cell lines in which PAK3 expression was induced by doxycycline thanks to a Tet-On expression system ( Figure 4A ). HA-PAK3 mutated protein expression was high after two days of antibiotic treatment, except for the A365E mutant, and not detectable in absence of doxycycline ( Figure 4B ). PAK3 protein stability was monitored by western blot after doxycycline withdrawal. Interestingly, the two K389N and G424R variants displayed a similar stability to those of the WT and the referent kinase-dead K297L proteins ( Figure 4C ).
Only the A365E mutation destabilized the protein, as previously shown (Magini et al., 2014) .
This probably explains the low expression level of this mutant, upon doxycycline treatment.
Thus, the two severe mutations maintain normal protein stability in contrast to the mild mutation, suggesting that catalytically inactive and stable proteins may induce cell defects by interfering with signalling pathways by protein/protein interaction in addition to the enzymatic loss of function.
increased compared to WT-expressing cells (WT median = 1; A365E median = 1.2, p≤0.001).
In contrast, the expression of the severe K389N and G424R PAK3 variants significantly increased the total number of paxillin-positive points per cell (WT median = 0.98; K389N median = 1.27, p≤0.001; G424R median = 1.17, p≤0.01; Figure 6B ) with an increase of both peripheral focal complexes (WT median = 1; K389N median = 1.3, p≤0.001; G424R median = 1.08, p≤0.05) and central focal adhesions per cell (WT median = 1; K389N median = 1.8, p≤0.001; G424R median = 1.4, p≤0.01) compared to WT-expressing cells ( Figure 6C and   6D ). After induction, we also observed an enrichment of the three kinase-dead PAK3 mutants in paxillin-positive points compared to WT condition, as previously reported for the K297L kinase-dead protein (as illustrated on figure 6A ) (Sells et al., 2000) . We conclude that both severe PAK3 mutants affect cell adhesion more severely than the mild A365E mutant.
Severe PAK3 mutations modify cell spreading and cell migration
While analyzing the effect of PAK3 variants on cell adhesion, we noticed that cells expressing kinase-dead mutants seemed to be more rounded after doxycycline induction in agreement with the role of PAK kinases in cell spreading (Price et al., 1998; Sells et al., 2000) . Thus, we analysed in the first five hours after seeding the cell circularity in noninduced cells and in PAK3 mutants-expressing cells. After fixation, COS7-Lv-PAK3 cells were labelled with fluorescent phalloidin in order to visualize the F-actin network and cell edges ( Figure 7A ). We measured cell area, perimeter and circularity that is defined by the two previous parameters. The expression of the three kinase-dead mutants triggered a significant increase in cell circularity (WT median = 0.89; A365E: median = 1.05; K389N: median = 1.28; G424R: median = 1.18; p≤0.001 for each mutant; Figure 7B ) and in cell area (WT median = 0.95; A365E: median = 1.08; K389N: median = 1.13; G424R: median = 1.28;
p≤0.001 for each mutant; Figure 7C ), compared to that of WT PAK3 expressing cells. No significant differences were observed for cell perimeter (data not shown). These results were all the more robust as doxycycline treatment of non-transduced COS7 cells induced a J o u r n a l P r e -p r o o f Journal Pre-proof decrease in cells area or circularity ( Figure S3C and S3D) and no effect on cell perimeter ( Figure S3E ).
Because adhesion points and cell spreading play a critical role in cell mobility, we analysed the effect of the expression of PAK3 variants on the migration of COS7-Lv-PAK3 cells with a wound healing test. PAK3 expression was induced by addition of doxycycline and proliferation was blocked with antimitotic AraC treatment. The gap relative closure was quantified 3 and 5 hours after inserts withdrawal. Expression of the WT PAK3 protein had no significant effect on the gap closure compared to the non-induced cells. In contrast, A365Eexpressing cells displayed a 20% reduction of migration observed after 5 h compared to noninduced cells whereas the two severe kinase-dead variants K389N and G424R displayed a more drastic decrease of migration from 3 h of 40 to 60% compared to their own non-induced cells (Figure 8 ). We verified that this decrease of migration is not due to an increase of apoptosis, by cleaved-caspase 3 labelling ( Figure S4 ). Together expression of severely pathogenic PAK3 variants impacted cell migration.
DISCUSSION
CCA may be associated with neurodevelopmental disorders, mainly with ID. Hundreds of genetic anomalies (copy number variations and gene mutations) have been identified by chromosomal microarray analyses and next generation sequencing in patients with CCA associated with ID, thereby generating a great nosological and etiological complexity (Edwards et al., 2014; Heide et al., 2017) . Moreover, different mutations in a single gene may lead to distinct clinical phenotypes, including ID with and without CCA, which raises the issue of the genotype/phenotype correlation. In the present work, we described a new family with ID and CCA found in several males, which strongly suggested an X-linked disorder.
Whole Exome Sequencing allowed us to identify a new mutation in the PAK3 gene located on the X chromosome. Several PAK3 mutations have been previously identified in patients with nonsyndromic ID highlighting the role of PAK3 in synaptic plasticity through a main J o u r n a l P r e -p r o o f Journal Pre-proof signalling pathway involving Rho-GTPases of the RAC and CDC42 family and targeting actin dynamics and dendritic spine remodeling (Allen et al., 1998; Bienvenu et al., 2000; Dubos et al., 2012; Gedeon et al., 2003; Kreis and Barnier, 2009; Ramakers, 2002; Rejeb et al., 2008; Sala and Segal, 2014) . This pathway also plays a crucial role in brain development since mutations in RAC1, CDC42 and PAK1 genes were identified in patients with ID and microcephaly or macrocephaly (Harms et al., 2018; Martinelli et al., 2018; Reijnders et al., 2017) . However the three PAK isoform seem to have specific and unique neuronal functions since their mutations lead to different symptoms, such as neurodevelopmental delay and microcephaly for PAK1, autism spectrum disorder for PAK2 and ID for PAK3 (Harms et al., 2018; Wang et al., 2018) . Interestingly, several PAK3 mutations were identified in patients with ID and structural brain anomalies (Table 1) . Microcephaly was reported in 13/29 individuals in 7 out 11 pedigrees and was associated with distinct mutations. Microcephaly did not correlate with the severity of ID, as illustrated by patients with the V294M variant and those with the R419X variant, both associated with microcephaly and mild ID (Allen et al., 1998; Muthusamy et al., 2017) .
Most mutations associated with microcephaly are missense mutations but two patients with the R419X nonsense mutation and two patients with a N-terminal frameshift also display this morphological defect. Concerning kinase activity, it is difficult to conclude that the loss of this function is sufficient to induce microcephaly. Indeed, patients harboring the A365E mutation which totally impairs the PAK3 enzymatic activity do not display microcephaly (Gedeon et al., 2003) . Interestingly, one mutation probably responsible for a relative gain of function through a partial activation of its kinase activity is associated with macrocephaly (Hertecant et al., 2017) . Concerning the severity of the pathogenicity of some missense mutations compared to nonsense or frame-shift mutations, we propose that the absence of protein has less pathogenic consequences than mutated variant proteins, because missense variants can adversely interfere with signalling pathways. Such hypothesis has already been J o u r n a l P r e -p r o o f Journal Pre-proof developed for PAK3 mutations that impact PAK dimer signalling and MAPK activation Magini et al., 2014) .
Anomalies of the corpus callosum were reported in three pedigrees with different PAK3 missense variants, including our study (Table 1) (Horvath et al., 2018; Magini et al., 2014) .
However, all patients did not undergo brain imaging, thus it is possible that some of the mutations listed in Table 1 may also be associated with CCA. Moreover, the thin corpus callosum described in the patient with the S527G variant may be a secondary cerebral atrophy induced by self-injuries (Horvath et al., 2018) . Thus, to date, only the K389N and G424R missense variants located in the catalytic domain and co-segregating with CCA in all individuals disrupt corpus callosum morphogenesis. Corpus callosum abnormalities are caused by developmental defects affecting neuronal proliferation and specification, cell migration and midline patterning, as well as by defects in axonal growth and guidance (Edwards et al., 2014) . It is well characterized that PAK kinases regulate several of these cellular processes, and more specifically that the PAK3 isoform controls neuroblast migration and axonal growth (Cobos et al., 2007; Kreis and Barnier, 2009; Liu et al., 2019) . To decipher biological processes underlying the phenotypical variability of PAK3-associated neurodevelopmental disorders, we compared the effects of the two K389N and G424R mutations associated with severe ID and CCA with the A365E PAK3 mutation previously reported in patients at the other edge of the clinical spectrum, i.e. with mild nonsyndromic ID.
We observed no correlation between the loss of kinase activity and the severity of the phenotype. This is in line with the severity of ID ranging from mild in patients with the A365E and W446S mutations that totally suppress the kinase activity to moderate or severe in those with the R67C mutation which retains it (Bienvenu et al., 2000; Gedeon et al., 2003; Peippo et al., 2007; Kreis et al., 2007; Magini et al., 2014) .
The G424R mutation is the second identified disease-causing mutation of the PAK3 kinase located in the activation segment, with the previously described Y427H mutation J o u r n a l P r e -p r o o f Journal Pre-proof (Hertecant et al., 2017) . A major determinant of the regulation of PAK and other kinases is the presence of an activation loop in the C-terminal lobe, which needs to be phosphorylated so that the active site can bind the substrate protein in a productive way. Phosphorylation results in the stabilization of this loop through electrostatic interactions between the phosphorylated threonine and an arginine of the C-terminal domain, and this involves a lasso movement of this loop whose hinges are glycine located at its two ends, one of which is Gly424. As we demonstrated, mutation of this residue totally suppresses the kinase activity, which can be explained by the inability of the activation loop of this mutant to adopt its active conformation. This mutation is thus anticipated to affect the structure and biochemistry of PAK3 in a different manner from other mutations of the catalytic domain involved in intellectual disabilities.
It was previously suggested that the stability of mutated PAK3 proteins may explain the severity of the associated phenotypes. We demonstrated that the A365E variant is unstable, a characteristic that was previously reported by Magini et al (Magini et al., 2014) . This is readily explained by its buried location, where mutation to a bulkier residue should alter folding of the C-terminal lobe of the kinase domain. In contrast, the K389N and G424R variants display normal stability compared to the WT protein, which may exacerbate their functional consequences by forming inactive complexes with partners. Again, this is consistent with their location at the surface of the kinase domain where they are not expected to impact significantly the stability of the protein (Sorrell et al., 2019) . Another non-exclusive hypothesis is that the G424R mutation may modify protein/protein interactions affecting signalling pathways.
PIX proteins are the main partners of group I PAK kinases and form supramolecular complexes with GIT proteins, and this complex plays a central role in neuronal signalling by regulating cell adhesion as well as migration, neurite extensions, and synaptic plasticity (Za et al., 2006) . Mutations of the αPIX gene located on the X chromosome are also responsible for J o u r n a l P r e -p r o o f Journal Pre-proof ID (Kutsche et al., 2000) . The regulation of PAK-PIX complexes involves the dimerization of PIXs, their phosphorylation and the combinatory of splice variants (Zhou et al., 2016) . Thus, activity-dependent autophosphorylation regulates formation of the PAK/PIX complexes so that kinase-dead mutants form more complexes than WT proteins (Feng et al., 2004) . By studying PAK3/PIXs interactions, we observed that the two PAK3 mutations inducing severe phenotypes tend to enhance PAK3 variant binding to αPIX and that their expression significantly increases the number of cell adhesion points suggesting abnormal turnover of adhesions. Adhesion point and integrin signalling are main regulators of cell migration which is often affected in CCA (Edwards et al., 2014; Zhou et al., 2016) . Further experiments showed that the expression of both K389N and G424R mutants strongly modified cell spreading and inhibited the cell migration tested in a wound healing assay. In PAK3 knockout mice, it was observed that absence of PAK3 protein did not modify oligodendrocyte progenitor (OPC) migration (Maglorius Renkilaraj et al., 2017) . While this may reflect differential molecular mechanisms of migration in these cell types, it is likely that missense mutations affect signalling in a different manner than the absence of the protein, for example by exerting dominant-negative or up-regulated effects. Altogether, these results suggest that mutations that might affect PAK3-PIX signalling may affect cell migration triggering brain morphological anomalies. Further studies with knock-in mouse model could bring a better comprehension of PIX function in pathophysiological mechanisms.
It is remarkable that although the missense K389N and G424R mutations are both expected to affect the kinase activity of PAK3, they display differences at both the clinical and cellular level. At the clinical level, ichthyosis is only diagnosed with the K389N variant whereas clinical traits such as ID, microcephaly, and ACC are observed with both PAK3 mutations.
Likewise, the K389N mutation was shown to impair the MAP kinase pathway, which was proposed to occur through a kinase-independent pathway (Magini) , while the G424R mutation has no effect on this pathway ( Figure SD5 ). Links between PAK3 mutations and J o u r n a l P r e -p r o o f Journal Pre-proof MAP kinase activation are complex and may involve both direct and indirect pathways, among which the PAK-PIX axis (Stockton et al., 2007) , and that these pathways are differentially affected by PAK3 mutations with different biochemical defects. Notably, the two mutations affect different determinants of the catalytic machinery, with K389N being located in the catalytic site and G424R in the activation loop. We conclude that several pathways such as MAP kinase and/or PIX pathways may be involved in the wide clinical spectrum associated with PAK3 variants.
In conclusion, our data bring important insight into a cellular mechanism possibly linking PAK3 mutations to brain dysgenesis. Remarkably, they highlight a remarkable correlation between structural and biochemical defects induced by each mutation to the severity of the associated intellectual disorders. This study also depicts the complexity of the relationship between genotype and phenotype, and strongly suggests that the patient phenotype may be due to the addition of synaptic dysfunctions and developmental defects and may be generated by the sum of biochemical defects such as kinase impairment, protein stability and partner-binding anomalies.
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fetus (III-7). The mother (II-5) carries this variant at heterozygous state. Familial segregation showed the PAK variant was not carried by a healthy maternal uncle (II-3). (B) Brain MRI of the patient (III-9) at the age of 6 years old showing short corpus callosum with severe splenium hypoplasia. Ala365 is buried inside the lobe, K389N is located at the tip of the loop that carries Arg386, a residue that is critical for the stabilization of the activation loop, and G424 is located at the hinge of the activation loop. The unphosphorylated activation loop is taken from the structure of unphosphorylated PAK1 and overlaid to phosphorylated PAK3, with residue too flexible to be seen in the crystal structure schematized by a dotted line. fs: frameshift Journal Pre-proof at 0, 3 and 5h after insert withdrawal. Gap closure for each mutant was normalized to its own control (non-induced cells). Three independent experiments were performed in duplicate and graphics represent the mean ± SEM. Parametric tests were used for statistical analysis after normality and variance equality verification; (*p<0,05; **p<0,01; ***p<0,001). mutations. The number of affected patients relative to the total number of examined people was reported: Macrocephaly, microcephaly and corpus callosum (CC) abnormality were indicated. The symptoms of the patient harbouring the R493C mutation were not described. † head circumference is -2.5 SD below the mean. NR: not reported.
FIGURE S1
The G424 residue is highly conserved in the human kinome and through the evolution. (A) Sequence alignment of PAK3 activation segment « DFGF…… APE » for different species where the G424 residue is located. (B) Sequence alignment of the activation segment from the human kinome. The G424 residue is conserved in approximately 57% of kinase family.
FIGURE S2
The G424 residue is located in a « Glycine favoured region » of the Ramachandran plot. Using the RAMPAGE server and PAK3's structure (PBD: 6FD3), we were allowed to determine the Phi and Psi angles of the G424 residue and observe that it is in a « Glycine favoured region ». So, this residue cannot, with a high probability, be switch by another amino acid. 
